Porton Advanced is a fully integrated cell and gene therapy CDMO, providing end-to-end support from early discovery through IIT, IND, and clinical phases to commercialization. 

We offer services from research-grade, GMP-like, to GMP, including:

-  Cell Therapy Solutions: In-vivo CAR-T, Ex- vivo CAR-T, UCAR-T, γδ T, TCR-T, TIL, Gene-editing T cells, NK, MSC, iPSC, HSC, RBC, and more

-  IVT mRNA, circRNA, saRNA production & LNP formulation

-  Lentivirus Packaging (suspension system, serum-free/animal-component-free) - tailored to meet the unique needs of in vivo CAR-T therapy development

-  Vector Cloning and Plasmid Production

-  Gene Editing (CRISPR-Cas9)

-  Oncolytic Virus Production

-  And other services tailored to your needs.

Porton Advanced also offers a full-service Investigator-Initiated Trial (IIT) platform in collaboration with non-clinical and clinical CRO partners. This enables biotech companies to set up IITs in China, generating efficacy data and first-in-human data (FIH).